Antibiotic susceptibility testing (Agar disk diffusion and agar dilution) of clinical isolates of Enterococcus faecalis and E. faecium: Comparison of Mueller-Hinton, Iso-Sensitest, and Wilkins-Chalgren agar media

Chemotherapy

Volumn 44, Issue 4, 1998, Pages 217-229

  Traub, Walter H ^a   Geipel, Udo ^a   Leonhard, Birgit ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Agar dilution test; Agar disk diffusion test (Bauer Kirby); Antibiotic susceptibility; Enterococcus faecalis; Enterococcus faecium; Iso Sensitest agar; Minimal inhibitory concentrations; Mueller Hinton agar; Wilkins Chalgren agar

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFEPIME; CEFIXIME; CEFOTAXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FOSFOMYCIN; FUSIDIC ACID; IMIPENEM; MEROPENEM; NITROFURANTOIN; OFLOXACIN; OXACILLIN; PENICILLIN G; PIPERACILLIN; PSEUDOMONIC ACID; RIFAMPICIN; SULBACTAM; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

AGAR GEL DIFFUSION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AGAR; ANTI-BACTERIAL AGENTS; CULTURE MEDIA; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EVALUATION STUDIES; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIOLOGICAL TECHNIQUES;

EID: 0031780963     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007118     Document Type: Article

References (64)

1. Hardie JM, Whiley RA: Classification and overview of the genera Streptococcus and Enterococcus. J Appl Microbiol 1997;83(suppl):1S-11S.
2. Murray BE: The life and times of the Enterococcus. Clin Microbiol Rev 1990;3:46-65.
3. Moellering RC: Emergence of Enterococcus as a significant pathogen. Rev Infect Dis 1992;14:1173-1178.
4. Johnson AP: The pathogenicity of enterococci. J Antimicrob Chemother 1994;33:1083-1089.
5. Wade JJ: Enterococcus faecium in hospitals. Eur J Clin Microbiol Infect Dis 1997;16:113-119.
6. Dunny GM: Pheromone-inducible conjugation in Enterococcus faecalis: Interbacterial and host-parasite chemical communication. J Bacteriol 1995;177:871-876.
7. Leclercq R: Enterococci acquire new kinds of resistance. Clin Infect Dis 1997;24(suppl 1):S80-S84.
8. Wade JJ, Uttley AHC: Resistant enterococci - Mechanisms, laboratory detection and control in hospitals. J Clin Pathol 1996;49:700-703.
9. Patterson JE, Sweeney AH, Simms M, Carley N, Mangi R, Sabetta J, Lyons RW: An analysis of 110 serious enterococcal infections - Epidemiology, antibiotic susceptibility, and outcome. Medicine 1995;74: 191-200.
10. Wright GD, Ladak P: Overexpression and characterization of the chromosomal aminoglycoside 6′-N-acetyltransferase from Enterococcus faecium. Antimicrob Agents Chemother 1997;41:956-960.
11. Murray BE, Mederski-Samoraj B: Transferable β-lactamase: A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest 1983;72:1168-1171.
12. Okamoto R, Okubo T, Inoue M: Detection of genes regulating β-lactamase production in Enterococcus faecalis and Staphylococcus aureus. Antimicrob Agents Chemother 1996;40:2550-2554.
13. Cercenado E, Vicente MF, Diaz MD, Sanchez-Carrillo C, Sanchez-Rubiales M: Characterization of clinical isolates of β-lactamase-negative highly ampicillin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1996;40:2420-2422.
14. Ligozzi M, Pittaluga F, Fontana R: Modification of penicillin-binding protein 5 associated with high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1996;40:354-357.
15. Kaufhold A, Klein R: Species identification and antibiotic susceptibility of enterococci isolated from clinical specimens of hospitalized patients. Zentralbl Baktertiol 1995;282:507-518.
16. Tankovic J, Mahjoubi F, Courvalin P, Duval J, Leclercq R: Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene. Antimicrob Agents Chemother 1996;40:2558-2561.
17. Lynch C, Courvalin P, Nikaido H: Active efflux of antimicrobial agents in wild-type strains of enterococci. Antimicrob Agents Chemother 1997;41:869-871.
18. Ridenhour MB, Fletcher HM, Mortensen JE, Daneo-Moore L: A novel tetracycline-resistant determinant, tet(U), is encoded on the plasmid pKQ10 in Enterococcus faecium. Plasmid 1996;35:71-80.
19. Leclercq R, Courvalin P: Resistance to glycopeptides in enterococci. Clin Infect Dis 1997;24:545-556.
20. Arthur M, Reynolds PE, Depardieu F, Evers S, Dutka-Malen S, Quintiliani R Jr, Courvalin P: Mechanisms of glycopeptide resistance in enterococci. J Infect 1996;32:11-16.
21. Struelens MJ: Multiple-resistant enterococci and Gram-negative bacteria: Tracking gene dissemination. Microb Drug Resist 1995;1:193-194.
22. Coque TM, Tomayko JF, Ricke SC, Okhyusen PC, Murray BE: Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob Agents Chemother 1996;40:2605-2609.
23. Jones RN, Marshall SA, Pfaller MA, Wilke WW, Hollis RJ, Erwin ME, Edmond MB, Wenzel RP, and the SCOPE Hospital Study Group: Nosocomial enterococcal blood stream infections in the SCOPE program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagn Microbiol Infect Dis 1997;29: 95-102.
24. Davis JM, Huycke MM, Wells CL, Bohnen JMA, Gadaleta D, Fichtl RE, Barie PS: Surgical Infection Society position on vancomycin-resistant Enterococcus. Arch Surg 1996; 131:1061-1068.
25. Devera ME, Simmons RDL: Antibiotic-resistant enterococci and the changing face of surgical infections. Arch Surg 1996;131:338-342.
26. George RC, Uttley AHC: Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s. Epidemiol Infect 1989;103: 403-413.
27. Uttley AHC, George RC, Naidoo J, Woodford N, Johnson AP, Collins CH, Morrison D, Gilfillan AJ, Fitch LE, Heptonstall J: High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989;103:173-181.
28. Fraise AP: The treatment and control of vancomycin resistant enterococci. J Antimicrob Chemother 1996;38:753-756.
29. Suppola JP, Volin L, Valtonen VV, Vaara M: Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies. Clin Infect Dis 1996;23:694-697.
30. Tonieporth NG, Roberts RB, John J, Hafner A, Riley LW: Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767-772.
31. Papanicolaou GA, Meyers BR, Meyers J, Mendelson MH, Lou W, Emre S, Sheiner P, Miller C: Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: Risk factors for acquisition and mortality. Clin Infect Dis 1996;23:760-766.
32. Bonten MJM, Gaillard CA, van Tiel FH, van der Geest S, Stobberingh EE: Colonization and infection with Enterococcus faecalis in intensive care units: The role of antimicrobial agents. Antimicrob Agents Chemother 1995;39:2783-2786.
33. Klare I, Heier H, Claus H, Reissbrodt R, Witte W: VanA-mediated high level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbiol Lett 1995;125:165-172.
34. McDonald LC, Kuehnert MJ, Tenover FC, Jarvis WR: Vancomycin-resistant enterococci outside the health-care setting: Prevalence, sources, and public health implications. Emerg Infect Dis 1997;3:311-317.
35. Traub WH, Leonhard B: Simple combined agar strip test (CAST) for detection of enterococcal susceptibility to ampicillin, moderate-or high-level gentamicin resistance, and potential additive activity of ampicillin plus gentamicin. Chemotherapy 1993;39:82-87.
36. Traub WH, Leonhard B, Bauer D: Enterococcus faecalis: In vitro activity of antimicrobial drugs, singly and combined, with and without defibrinated human blood, against high-level-gentamicin-resistant isolates. Chemotherapy 1993;39:248-253.
37. Traub WH, Leonhard B, Bauer D: Enterococcus faecium: In vitro activity of antimicrobial drugs, single and combined, with and without defibrinated human blood, against multiple-antibiotic-resistant strains. Chemotherapy 1993;39:254-264.
38. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disk Susceptibility Tests, 5. NCCLS Document M2-A6. Villanova, NCCLS, 1997.
39. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, ed 3. NCCLS Document M7-A3. Villanova, NCCLS, 1993.
40. Facklam RR, Sahm DF: Enterococcus; in Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds): Manual of Clinical Microbiology, ed 6. Washington, American Society for Microbiology, 1995, pp 308-314.
41. Bourgault A-M, Rosenblatt JE: Characterization of anaerobic gram-negative bacilli by using rapid slide tests for β-lactamase production. J Clin Microbiol 1979;9:654-656.
42. Bauer AW, Kirby WMM, Sherris JC, Turck M: Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966;45:493-496.
43. Traub WH, Spohr M: Fosfomycin: Interpretation of inhibition zones obtained with the Bauer-Kirby agar disk diffusion susceptibility test. Chemotherapy 1983;29:208-212.
44. Finlay JE, Miller LA, Poupard JA: Interpretive criteria for testing susceptibility of staphylococci to mupirocin. Antimicrob Agents Chemother 1997;41:1137-1139.
45. Barry AL, Thornsberry C, Jones RN, Fuchs PC, Gavan TL, Gorbach EH: Reassessment of the 'class' concept of disk susceptibility testing. Cephalothin disks versus minimal inhibitory concentrations with eleven cephalosporins. Am J Clin Pathol 1978;70:909-913.
46. Traub WH, Kohl K-H, Spohr M: In vitro activity of three fluoroquinolones against enterococci and Pseudomonas aeruginosa: Modified categorization system for discrepant broth dilution and agar disk diffusion test results. Chemotherapy 1988;34:101-106.
47. Traub WH, Leonhard B: Comparison of Wilkins-Chalgren medium supplemented with nicotinamide adenine dinucleotide and Haemophilus test medium for susceptibility testing of clinical Haemophilus isolates. Chemotherapy 1995;41:437-447.
48. Kohnen PC, Patel R, Uhl JR, Garin KM, Hopkins MK, Wegener LT, Cockerill FR: Comparison of agar dilution, broth microdilution, E-test, disk diffusion, and automated Vitek methods for testing susceptibilities of Enterococcus spp. to vancomycin. J Clin Microbiol 1997;35: 3258-3263.
49. Landman D, Quale JM: Management of infections due to resistant enterococci: A review of therapeutic options. J Antimicrob Chemother 1997;40:161-170.
50. Goodhart GL: In vivo v in vitro susceptibility of enterococcus to trimethoprim-sulfamethoxazole. A pitfall. JAMA 1984;252:2748-2749.
51. Elsner H-A, Krüger W, Laufs R, Mack D: Septicemia due to susceptible Enterococcus faecalis despite prophylaxis with trimethoprim-sulfamethoxazole. Eur J Clin Microbiol Infect Dis 1997;16:620-622.
52. Cormican MG, Biedenbach D, Jones RN: Reevaluation of contemporary laboratory methods for detection of antimicrobial resistance among enterococci. Clin Microbiol Infect 1996;1:190-194.
53. Endtz HP, van den Braak N, van Belkum A, Goessens WH, Kreft D, Stroebel AB, Verbrugh HA: Comparison of eight methods to detect vancomycin resistance in enterococci. J Clin Microbiol 1998;36:592-594.
54. Herrera-Insua I, Jacques-Palaz K, Murray BE, Rakita RM: Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium. Antimicrob Agents Chemother 1996;40:886-890.
55. Chow JW, Davidson A, Sanford E, Zervos MJ: Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Clin Infect Dis 1997;24:91-92.
56. Chow JW, Donabedian SM, Zervos MJ: Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect 1997; 24:90-91.
57. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC: In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996;40:1745-1747.
58. Fraise AP, Brenwald N, Andrews JM, Wise R: In vitro activity of two glycylcyclins against enterococci resistant to other agents. J Antimicrob Chemother 1995;35:877-881.
59. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K: Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23: 1020-1025.
60. Chadwick PR, Oppenheim BA: Controlling glycopeptide-resistant enterococci. Clin Microbiol Infect 1997;3:7-11.
61. Lai KK: Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 1996;156: 2579-2584.
62. Beezhold DW, Slaughter S, Hayden MK, Matushek M, Nathan C, Trenholme GM, Weinstein RA: Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia. Clin Infect Dis 1997;24:704-706.
63. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP: Vancomycin-resistant enterococcal bacteriemia: Natural history and attributable mortality. Clin Infect Dis 1996; 23:1234-1239.
64. Mekonen ET, Noskin GA, Hacek DM, Peterson LR: Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb Drug Resist 1995;1:249-253.